SC
MDGL icon

Stephens Consulting’s Madrigal Pharmaceuticals MDGL Stock Holding History

Stephens Consulting’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$606 – 860
2025
Q2 		$606 Sell
2
-3
-60% -$894 ﹤0.01% 856
2025
Q1 		$1.66K Buy
+5
New +$1.64K ﹤0.01% 484

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Stephens Consulting's MDGL Position: Q3 2025 in Review

Stephens Consulting sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 2 shares — an estimated $606 sold.

Stephens Consulting first reported a position in MDGL in Q1 2025 and held it in 2 quarters. The position peaked at $1.66K in Q1 2025. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Stephens Consulting reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 2 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $606.
  • Stephens Consulting first reported a position in Madrigal Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Stephens Consulting's Madrigal Pharmaceuticals position peaked at $1.66K in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.